The company had encouraging results for its breast cancer tests and provided an update on the development of its bladder cancer test.
With a recent draft guidance from Medicare contractor Palmetto, and $6.1 million in new funding, Indi hopes to launch the test in the next six to nine months.
Palmetto GBA has issued a draft local coverage determination for the company's Xpresys Lung 2 lung cancer test, an update version of its original Xpresys test.
A subset of mutation-associated neoantigens appeared to be lost from lung or head and neck tumors that became resistant to anti-PD1 or anti-PD1 and anti-CLTA4 therapy.
The Toronto company raised C$721,000 of its previously announced offering that targeted up to C$3 million.
The research team established that its model can be used to determine the optimal dose of radiation therapy for individual patients.
In PNAS this week: circulating tumor cells may be useful for tracking disease, analysis of demethylation in endosperm seed tissue, and more.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
The arrangement allows Perthera to expand the scope of its molecular profiling work while helping the LCA provide more patients access to such testing.
These services include genomic, proteomic, and phosphoproteomic testing of patient tumors as well as expert analysis using this molecular data to guide therapy.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.